ARTICLE | Clinical News
PEG-SN38: Phase I final data
November 23, 2009 8:00 AM UTC
Final data from a dose-escalation Phase I trial in 39 patients with advanced solid tumors showed that IV EZN-2208 resulted in 9 cases of stable disease lasting >90 days. The MTD and recommended Phase ...